← Leaderboards
Jered C Garrison
University Of Missouri-Columbia
$6,180,863
Attributed
$6,804,780
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,804,780 · 8
By mechanism
R01$4,500,414 · 3
R00$732,062 · 1
P20$586,062 · 1
R41$400,000 · 1
R21$390,858 · 1
K99$195,384 · 1
Top collaborators
- Maneesh Jain2 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Marc Robillard$289,897
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMouse ModelTumorMalignant NeoplasmsDesignTechnologyIn VitroEvaluationPropertyAnalogLabelMolecular WeightDoseToxic EffectMaximum Tolerated DoseTissuesReceptorResidenceCessation Of LifeCancer EtiologyBiodistributionRadiation TherapyTherapeutic EvaluationPeptides
Grant awards (22)
Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer$626,716
R01 · FY2025 · CA · contact PI
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer$328,106
R01 · FY2025 · CA · contact PI
Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer$621,119
R01 · FY2024 · CA · contact PI
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer$311,703
R01 · FY2024 · CA · contact PI
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer$321,544
R01 · FY2023 · CA · contact PI
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer$321,285
R01 · FY2022 · CA · contact PI
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer$408,501
R01 · FY2021 · CA · contact PI
Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma$400,000
R41 · FY2021 · CA · contact PI
Development of a Theranostic Nanomedicine Construct for Ovarian Cancer$390,858
R21 · FY2021 · CA · contact PI
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S$312,288
R01 · FY2018 · CA · contact PI
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S$312,288
R01 · FY2017 · CA · contact PI
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S$312,288
R01 · FY2016 · CA · contact PI
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S$312,288
R01 · FY2015 · CA · contact PI
Development of Metabolically Active Linkers (MALs) to Improve Diagnostic and Radiotherapeutic HPMA Copolymers$178,710
P20 · FY2015 · GM · contact PI
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S$312,288
R01 · FY2014 · CA · contact PI
Project 6 - Development of Metabolically Active Linkers (MALs) to Improve Diagno$182,889
P20 · FY2014 · GM · contact PI
Project 6 - Development of Metabolically Active Linkers (MALs) to Improve Diagno$224,463
P20 · FY2013 · GM · contact PI
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer$241,531
R00 · FY2012 · CA · contact PI
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer$241,531
R00 · FY2011 · CA · contact PI
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer$249,000
R00 · FY2010 · CA · contact PI
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer$99,408
K99 · FY2009 · CA · contact PI
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer$95,976
K99 · FY2008 · CA · contact PI